Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

Keywords

Medicine, Trastuzumab, Breast cancer, Oncology, Systemic therapy

References

• Axilladissektion vs. keine Axilladissektion bei Frauen mit invasivem Brustkrebs und positiven SentinellymphknotenTanja Fehm, D. Wallwiener — 2012
• Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.Marco Colleoni, Marco Colleoni, Shari Gelber — 2006
• Gene-expression signatures in breast cancer.Daniel B Kopans — 2003
• The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trialSøren M. Bentzen — 2008
• RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesisEva González‐Suárez, Allison P. Jacob, Jon C. Jones — 2010
• microRNA-205 regulates HER3 in human breast cancer.Marilena V. Iorio, Patrizia Casalini, Claudia Piovan — 2009
• Fibroblast-recruited, tumor-infiltrating CD4+ T cells stimulate mammary cancer metastasis through RANKL-RANK signalingWei Phin Tan, Weizhou Zhang, Amy Strasner — 2011
• Autologous fat transplantation in patients with breast cancer: "silencing" or "fueling" cancer recurrence?Visnu Lohsiriwat, Giuseppe Curigliano, Mario Rietjens — 2011
• Abstract S3-3: First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast CancerJosé Baselga, Ian Bradbury, Holger Eidtmann — 2010
• Results of Chemotherapy Alone, with Sequential or Concurrent Addition of 52 Weeks of Trastuzumab in the NCCTG N9831 HER2-Positive Adjuvant Breast Cancer Trial.Edith A. Perez, Vera J. Suman, Nancy E. Davidson — 2009
• Abstract S3-2: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ('NeoSphere')Luca Gianni, Tadeusz Pieńkowski, Y-H Im — 2010
• Reproductive History and Risk of Three Breast Cancer Subtypes Defined by Three BiomarkersAmanda I. Phipps, Diana S.M. Buist, Kathleen E. Malone — 2010
• Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.Luca Gianni, W. Eiermann, Semiglazov Vf — 2010
• The San Antonio Breast Cancer SymposiumTristin Abair, Susan Peck, Joyce O’Shaughnessy — 2011
• Gail's model as first step for early diagnosis: National Cancer Institute of Naples experienceS. Formenti — 2009
• Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancerF. Jänicke, Manfred Schmitt, L. Pache — 2005
• Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.Rosalba Torrisi, Anna Cardillo, Giuseppe Cancello — 2010
• Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer.Bernard Fisher, Madeline Bauer, Richard G. Margolese — 1985
• Adjuvant Chemotherapy in Older Women with Early-Stage Breast CancerHyman B. Muss, Donald A. Berry, Constance Cirrincione — 2009
• Breast cancer management in low resource countries (LRCs): Consensus statement from the Breast Health Global InitiativeChristos Sotiriou — 2011

Cited by

• The prognostic significance of LIAISON(R) CA15-3 assay in primary breast cancer.Benjamin Nisman, Ofra Maimon, Tanir M. Allweis — 2013
• Genexpressionssignaturen beim MammakarzinomMarcus Schmidt — 2013
• A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?Ayham Arab Oghli, Helmut Steveling — 2010
• [Modern pharmacological therapy of breast cancer].洋 保坂, 満 金野 — 2012
• Omission of Axillary Dissection after a Positive Sentinel Node Dissection may Influence Adjuvant Chemotherapy Indications in Operable Breast Cancer Patients克幸 鈴木 — 2012
• Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane.Ángel Guerrero, J.G. Gavila, Elizabeth Folkerd — 2013
• Update on neoadjuvant/preoperative therapy of breast cancer: experiences from the German Breast GroupBhumikaben Patel — 2013
• [Trastuzumab in early breast cancer].勝美 齊藤, 就一 長谷川, 暁洋 伏見 — 2013
• 89Zr-Bevacizumab PET Imaging in Primary Breast CancerSietske B.M. Gaykema, Adrienne H. Brouwers, Marjolijn N. Lub–de Hooge — 2012
• Adjuvant trastuzumab for 6 months is effective in patients with HER2-positive stage II or III breast cancer.R E Leech, Martha R. Bell, J. G. Evans — 2013
• Differential distribution of microRNAs in breast cancer grouped by clinicopathological subtypes.Sujan Shrestha, John P. Moore, José Abdelnour-Nocera — 2013
• Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype健太 滝沢, 雄二 長谷見, 伸一 土屋 — 2013
• Detection of internal mammary lymph node metastasis with 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III breast cancerPierrette Dayhaw‐Barker — 2014
• Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.E Fischer — 2014
• HER2-enriched tumors have the highest risk of local recurrence in Chinese patients treated with breast conservation therapy.R. L. Bannister, N. S. Cheruvu, D.A. Little — 2014
• Primary systemic treatment and concomitant low dose radiotherapy for breast cancer: final results of a prospective phase II study.Juan Carlos Rubiales Moreno — 2014
• Postmastectomy radiotherapy: indications and implications.Siún Walsh, Aoïfe Lowery, R S Prichard — 2014
• The prognostic value of lymph node status among breast cancer subtypes.Guo‐Shiou Liao, Yu‐Ching Chou, Huan-Ming Hsu — 2015
• Can mammographic and sonographic imaging features predict the Oncotype DX™ recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers?Monica Yepes, A. Pat Romilly, Fernando Collado‐Mesa — 2014
• The Clinical Impact of 21-Gene Recurrence Score on Treatment Decisions for Patients with Hormone Receptor-Positive Early Breast Cancer in KoreaPedro Ballester — 2014

Related papers

• A clinical study of 57 patients with natural killer/T-cell lymphoma,nasal typeRuo Wang — 2008
• Correlation between response to cisplatinum‐combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neckJohn F. Ensley, John R. Jacobs, Arthur Weaver — 1984
• The Influence of Radiotherapy and Chemotherapy on Platelet Parameters in Tumor Patients and Its SignificanceSun Changju — 2008
• EFFECTS OF CHEMOTHERAPY AND RADIOTHERAPY ON BLOOD COMPONENTS OF BREAST CANCER PATIENTSBaydaa Taher Sih — 2018
• Effect of Operation,Radiotherapy and Chemotherapy on Blood Stasis Syndrome of CancerYang Don — 2015
• Postoperative Concurrent Radiotherapy and Chemotherapy for Malignant Cerebral GliomaZeng Xiang-fu — 2008
• Systemic adjuvant therapies and radiotherapy to the conserved breast: strategies revisited.Harry Bartelink — 2007
• Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastasesXiaojing Yang, Hanru Ren, Yi Xu — 2023
• Neoadjuvant (presurgical) therapy for renal cell carcinoma: A new treatment paradigm for locally advanced and metastatic diseaseChristopher G. Wood, Vitaly Margulis — 2009